Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 16 of 16 entries
View as:

Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate

Phase: N/A Priority: Normal
NCT ID: NCT01792687 Org: User:
Start: 02/05/13 End: 02/13/24 Due: 02/13/25

14C-ARN-509 Microtracer Label AME and Absolute BA Study

Phase: N/A Priority: Normal
NCT ID: NCT01822041 Org: User:
Start: 03/31/13 End: 06/30/13 Due: 06/30/14

A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT02031666 Org: User:
Start: 12/31/13 End: 04/30/14 Due: 04/30/15

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

Phase: N/A Priority: Normal
NCT ID: NCT02489318 Org: User:
Start: 11/27/15 End: 12/31/27 Due: 12/31/28

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Phase: N/A Priority: Normal
NCT ID: NCT02531516 Org: User:
Start: 11/19/15 End: 12/29/28 Due: 12/29/29

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01946204 Org: User:
Start: 10/14/13 End: 12/31/27 Due: 12/31/28

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase: N/A Priority: Normal
NCT ID: NCT02257736 Org: User:
Start: 11/26/14 End: 12/31/27 Due: 12/31/28

Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT02160756 Org: User:
Start: 06/30/14 End: 11/30/14 Due: 11/30/15

Study to Assess Drug-Drug Interaction Between Itraconazole or Gemfibrozil and JNJ-56021927

Phase: N/A Priority: Normal
NCT ID: NCT02230033 Org: User:
Start: 09/30/14 End: 12/31/14 Due: 12/31/15

An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03523338 Org: User:
Start: - End: - Due: -

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02123758 Org: User:
Start: 07/09/14 End: 12/31/27 Due: 12/31/28

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Phase: N/A Priority: Normal
NCT ID: NCT02578797 Org: User:
Start: 12/18/15 End: 10/13/22 Due: 10/13/23

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02592317 Org: User:
Start: 02/12/16 End: 12/31/27 Due: 12/31/28

A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT02524717 Org: User:
Start: 08/13/15 End: 02/09/17 Due: 02/09/18

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01790126 Org: User:
Start: 03/04/13 End: 03/01/19 Due: 03/01/20

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Phase: N/A Priority: Normal
NCT ID: NCT01171898 Org: User:
Start: 07/26/10 End: 12/31/27 Due: 12/31/28